Arcus Biosciences, Inc. Income (Loss) from Equity Method Investments
Arcus Biosciences, Inc. (RCUS) reported Income (Loss) from Equity Method Investments of -$613.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2022-02-23.
Discontinued › Income Statement › Other Income
us-gaap:IncomeLossFromEquityMethodInvestments · last filed 2022-02-23
- Arcus Biosciences, Inc. income (loss) from equity method investments for the quarter ending 2020-12-31 was $0.00.
- Arcus Biosciences, Inc. income (loss) from equity method investments for the quarter ending 2020-09-30 was $0.00.
- Arcus Biosciences, Inc. income (loss) from equity method investments for the quarter ending 2020-06-30 was -$131.00K.
- Arcus Biosciences, Inc. income (loss) from equity method investments for the quarter ending 2020-03-31 was -$482.00K.
- Arcus Biosciences, Inc. income (loss) from equity method investments for fiscal 2020 was -$613.00K.
- Arcus Biosciences, Inc. income (loss) from equity method investments for fiscal 2019 was -$1.20M.
- Arcus Biosciences, Inc. income (loss) from equity method investments for fiscal 2018 was -$886.00K.
- Arcus Biosciences, Inc. income (loss) from equity method investments for fiscal 2017 was -$416.00K.
| Period end | Income (Loss) from Equity Method Investments 3 month | Income (Loss) from Equity Method Investments 6 month | Income (Loss) from Equity Method Investments 9 month | Income (Loss) from Equity Method Investments 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $0.00 derived: sum of 2 quarters · filed 2022-02-23 | -$131.00K derived: sum of 3 quarters · filed 2022-02-23 | -$613.00K 10-K · filed 2022-02-23 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | -$131.00K derived: sum of 2 quarters · filed 2021-11-08 | -$613.00K 10-Q · filed 2021-11-08 | -$613.00K derived: sum of 4 quarters · filed 2022-02-23 |
| 2020-06-30 | -$131.00K 10-Q · filed 2021-08-05 | -$613.00K 10-Q · filed 2021-08-05 | -$613.00K derived: sum of 3 quarters · filed 2022-02-23 | -$970.00K derived: sum of 4 quarters · filed 2022-02-23 |
| 2020-03-31 | -$482.00K 10-Q · filed 2021-05-05 | -$482.00K derived: sum of 2 quarters · filed 2022-02-23 | -$839.00K derived: sum of 3 quarters · filed 2022-02-23 | -$1.25M derived: sum of 4 quarters · filed 2022-02-23 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | -$357.00K derived: sum of 2 quarters · filed 2022-02-23 | -$769.00K derived: sum of 3 quarters · filed 2022-02-23 | -$1.20M 10-K · filed 2022-02-23 |
| 2019-09-30 | -$357.00K 10-Q · filed 2020-11-05 | -$769.00K derived: sum of 2 quarters · filed 2020-11-05 | -$1.20M 10-Q · filed 2020-11-05 | -$1.52M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | -$412.00K 10-Q · filed 2020-08-06 | -$844.00K 10-Q · filed 2020-08-06 | -$1.17M derived: sum of 3 quarters · filed 2021-02-25 | -$1.35M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | -$431.00K 10-Q · filed 2020-05-05 | -$754.00K derived: sum of 2 quarters · filed 2021-02-25 | -$940.00K derived: sum of 3 quarters · filed 2021-02-25 | -$1.09M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | -$323.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$509.00K derived: sum of 2 quarters · filed 2021-02-25 | -$660.00K derived: sum of 3 quarters · filed 2021-02-25 | -$886.00K 10-K · filed 2021-02-25 |
| 2018-09-30 | -$186.00K 10-Q · filed 2019-11-05 | -$337.00K derived: sum of 2 quarters · filed 2019-11-05 | -$563.00K 10-Q · filed 2019-11-05 | -$719.00K derived: sum of 4 quarters · filed 2019-11-05 |
| 2018-06-30 | -$151.00K 10-Q · filed 2019-08-06 | -$377.00K 10-Q · filed 2019-08-06 | -$533.00K derived: sum of 3 quarters · filed 2019-08-06 | -$652.00K derived: sum of 4 quarters · filed 2019-08-06 |
| 2018-03-31 | -$226.00K 10-Q · filed 2019-05-02 | -$382.00K derived: sum of 2 quarters · filed 2019-05-02 | -$501.00K derived: sum of 3 quarters · filed 2019-05-02 | -$572.00K derived: sum of 4 quarters · filed 2019-05-02 |
| 2017-12-31 | -$156.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-05 | -$275.00K derived: sum of 2 quarters · filed 2019-03-05 | -$346.00K derived: sum of 3 quarters · filed 2019-03-05 | -$416.00K 10-K · filed 2019-03-05 |
| 2017-09-30 | -$119.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | -$190.00K derived: sum of 2 quarters · filed 2018-11-08 | -$260.00K 10-Q · filed 2018-11-08 | |
| 2017-06-30 | -$71.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | -$141.00K 10-Q · filed 2018-08-06 | ||
| 2017-03-31 | -$70.00K 10-Q · filed 2018-05-09 | |||
| 2016-12-31 | $0.00 10-K · filed 2019-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |